Literature DB >> 2893692

Adverse reactions in the skin from anti-hypertensive drugs.

K Thestrup-Pedersen1.   

Abstract

Anti-hypertensive drugs, including diuretics and beta-blocking drugs, belong to a group of therapeutics used by about a fourth of the Danish population. As with cytostatics, antibiotics, and topical remedies, they rather frequently cause adverse drug reactions (ADR) in the skin. No exact statistical information is available concerning the extent of such side effects. The information obtained by Danish National Board of Health's Committee on Adverse Drug Reactions shows that 10-60% of ADR from diuretics, beta-blocking agents, and anti-hypertensive drugs are dermatological. The skin symptoms are not unique for any specific drug. But certain symptoms occur more frequently than others. Thiazides can give vasculitis, a phototoxic/-allergic eruption, erythema multiforme, or eczema. The combination of amiloride (5 mg) and hydrochlorothiazide (50 mg) carries the highest number of recorded ADR; 59% of these are in the skin. Half of the skin ADR are phototoxic eczema. Furosemide may give eczema, purpura, a bullous eruption, or Steven-Johnson's syndrome in rare cases. Methyldopa can induce eczematous eruptions on hands and feet, a lichenoid eruption, a lupus erythematosus-like eruption, or purpura. Hydralazine may give lupus erythematosus-like eruptions, eczema, or urticaria. Non-specific beta-blocking drugs can induce a morbilliform rash and may aggravate psoriasis. Captopril may induce pruritus in up to 15% of the patients and skin eruptions in 2%. The most serious dermatological side effect, exfoliative dermatitis, is very rarely seen following the use of anti-hypertensive drugs or diuretics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2893692

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


  10 in total

1.  Cutaneous adverse reaction to furosemide treatment: new clinical findings.

Authors:  Pablo Gómez Ochoa; María Teresa Verde Arribas; Javier Miana Mena; Manuel Gascón Pérez
Journal:  Can Vet J       Date:  2006-06       Impact factor: 1.008

2.  Metoclopramide-induced delayed non-thrombocytopenic purpuric rash.

Authors:  S Upputuri; S Prasad
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

3.  Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system.

Authors:  Gabriela Mazzanti; Paola Angela Moro; Emanuel Raschi; Roberto Da Cas; Francesca Menniti-Ippolito
Journal:  Br J Clin Pharmacol       Date:  2017-01-19       Impact factor: 4.335

4.  Hydrochlorothizide-induced acute generalised exanthematous pustulosis presenting with bilateral periorbital impetigo.

Authors:  Leo E Reap; Cassandra Rodd; Jose Larios; Michael Marshall
Journal:  BMJ Case Rep       Date:  2019-02-11

Review 5.  Eczematous Drug Eruptions.

Authors:  Amy E Blum; Susan Burgin
Journal:  Am J Clin Dermatol       Date:  2021-02-15       Impact factor: 7.403

6.  Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.

Authors:  A V Mezentsev; S A Bruskin; A G Soboleva; V V Sobolev; E S Piruzian
Journal:  Int J Biomed Sci       Date:  2013-09

7.  Association between changes in facial flushing and hypertension across drinking behavior patterns in South Korean adults.

Authors:  Yu Shin Park; Soo Hyun Kang; Eun-Cheol Park; Suk-Yong Jang
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-04-19       Impact factor: 2.885

Review 8.  Minimal change nephrotic syndrome in an 82 year old patient following a tetanus-diphteria-poliomyelitis-vaccination.

Authors:  Christian Clajus; Janine Spiegel; Verena Bröcker; Christos Chatzikyrkou; Jan T Kielstein
Journal:  BMC Nephrol       Date:  2009-08-05       Impact factor: 2.388

9.  Molecular signaling and targets from itch: lessons for cough.

Authors:  Pamela Colleen Lavinka; Xingzhong Dong
Journal:  Cough       Date:  2013-03-06

10.  Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study.

Authors:  A Ø Jensen; H F Thomsen; M C Engebjerg; A B Olesen; H T Sørensen; M R Karagas
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.